PolyPid (PYPD) Competitors

Pulmonx (NASDAQ:LUNG) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.

Does the media refer more to LUNG or PYPD?

In the previous week, PolyPid had 11 more articles in the media than Pulmonx. MarketBeat recorded 23 mentions for PolyPid and 12 mentions for Pulmonx. Pulmonx's average media sentiment score of 1.53 beat PolyPid's score of 0.69 indicating that Pulmonx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulmonx	8 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
PolyPid	3 Very Positive mention(s)	0 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Is LUNG or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to Pulmonx's net margin of -67.31%. Pulmonx's return on equity of -55.36% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulmonx	-67.31%	-55.36%	-33.53%
PolyPid	N/A	-624.10%	-129.28%

Do analysts prefer LUNG or PYPD?

Pulmonx presently has a consensus target price of $11.53, suggesting a potential upside of 253.53%. PolyPid has a consensus target price of $11.25, suggesting a potential upside of 225.14%. Given Pulmonx's higher possible upside, equities research analysts clearly believe Pulmonx is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.63
PolyPid	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Which has better earnings & valuation, LUNG or PYPD?

PolyPid has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$87.47M	1.50	-$60.84M	-$1.44	-2.26
PolyPid	N/A	N/A	-$29.02M	-$4.30	-0.80

Which has more risk and volatility, LUNG or PYPD?

Pulmonx has a beta of 0.52, indicating that its share price is 48% less volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.25, indicating that its share price is 25% more volatile than the S&P 500.

Does the MarketBeat Community believe in LUNG or PYPD?

Pulmonx received 4 more outperform votes than PolyPid when rated by MarketBeat users. However, 81.40% of users gave PolyPid an outperform vote while only 46.99% of users gave Pulmonx an outperform vote.

Company	Underperform	Outperform
Pulmonx	Outperform Votes 39 46.99%	Underperform Votes 44 53.01%
PolyPid	Outperform Votes 35 81.40%	Underperform Votes 8 18.60%

Do insiders and institutionals believe in LUNG or PYPD?

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Pulmonx and PolyPid tied by winning 9 of the 18 factors compared between the two stocks.